department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Prelude Therapeutics Inc ($PRLD) · pharmadog

PUBLIC COMPANY

$PRLDPrelude Therapeutics Inc

Wilmington, DE, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 1

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Prelude Therapeutics Inc jobs →

News

no news has mentioned this company yet

identifiers

ticker

$PRLD

SEC CIK

0001678660

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

Active trials

phase1A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasmsrecruitingn=100
phase2A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutationterminatedn=6
phase1A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutationterminatedn=42
phase1A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignanciescompletedn=86
phase1PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutationcompletedn=135
phase1A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumorscompletedn=22
phase1PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignanciesterminatedn=21
phase1A Study of PRT2527 in Participants With Advanced Solid Tumorscompletedn=30

more trials →

$PRLD

Insider activity

source: SEC Form 4

90d open-market buys

$25.00M

4 transactions

90d open-market sells

$0

0 transactions

net (buys − sells)

+$25.00M

non-derivative only

open-market buys + sells

Apr 21, 26BUYBAKER BROS. ADVISORS LP· 10% owner2,137,651 sh @ $4.44$9.49M↗
Apr 21, 26BUYORBIMED ADVISORS LLC· 1,689,189 sh @ $4.44$7.50M↗
Apr 21, 26BUYBonita David P· 1,689,189 sh @ $4.44$7.50M↗
Apr 21, 26BUYBonita David P· 1,126,126 sh @ $4.44$5.00M↗
Apr 21, 26BUYORBIMED ADVISORS LLC· 1,126,126 sh @ $4.44$5.00M↗
Apr 21, 26BUYBAKER BROS. ADVISORS LP· 10% owner114,601 sh @ $4.44$509K↗

routine RSU / option mechanics (4)

Feb 4, 26grantVaddi Krishna · CEO837,000 sh
Feb 4, 26grantCombs Andrew · Chief Chemistry Officer230,000 sh
Feb 4, 26grantScherle Peggy · Chief Scientific Officer230,000 sh
Feb 4, 26grantLim Bryant David · CLO, CFO, Corp Sec.275,000 sh

Data sources

last refreshed 57m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?